Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 9/20 | 0.37 |
| ▸ | TNF | P01375 | 2/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561843 | 0.79 | MAPT (0.43) | MEN1KMT2AIL1BCACNA1GKCNA5 | |
| SCHEMBL17240868 | 0.77 | IL1B (0.36) | MEN1KMT2AIL1BTNFCACNA1G | |
| SCHEMBL28844931 | 0.77 | LMNA (0.33) | MEN1KMT2AIL1BTNFCACNA1G | |
| SCHEMBL22654945 | 0.75 | IL1B (0.51) | IL1BTNFEDNRA | |
| SCHEMBL17240865 | 0.73 | IL1B (0.33) | IL1BTNFCACNA1GKCNA5 | |
| SCHEMBL12287314 | 0.73 | TRPA1 (0.42) | IL1BTNF | |
| SCHEMBL2560374 | 0.73 | SMO (0.39) | MEN1KMT2AIL1BTNF | |
| SCHEMBL2563023 | 0.73 | NPC1 (0.46) | MEN1KMT2AIL1BTNF | |
| SCHEMBL2559850 | 0.72 | IL1B (0.33) | IL1BTNFCACNA1GKCNA5 | |
| SCHEMBL12288231 | 0.72 | NPC1 (0.51) | MEN1KMT2AIL1BTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107266419-B | Certain amino-pyridazines, compositions thereof, and methods of use thereof | 赛特凯恩蒂克公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-3127541-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3127541-B1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS INC (US) | 2019-07-17 | — | — | EP | disclosed |
| US-10076519-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | CYTOKINETICS INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | CYTOKINETICS INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | CYTOKINETICS INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-9604965-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604965-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604965-B2 | Substituted pyridazines as skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | ASHCRAFT LUKE W (US) | 2015-11-12 | — | — | US | disclosed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969346-B2 | Amino-pyridazine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. | 2013-06-06 | — | — | US | disclosed |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. | 2013-06-06 | — | — | US | disclosed |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. | 2013-06-06 | — | — | US | disclosed |
| EP-2563365-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | Cytokinetics, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011133882-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133882-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281621-A1 | SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS | MUSK, PYGM, GYS1 | MEN1 3791/4885KMT2A 3136/4885IL1B 2567/4885 |
| US-10076519-B2 | Substituted pyridazines as skeletal muscle modulators | MUSK, PYGM, GYS1 | MEN1 3791/4885KMT2A 3136/4885IL1B 2567/4885 |
| US-20130143862-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE | SLC7A1, F12, C5 | MEN1 730/4885KMT2A 2351/4885IL1B 1963/4885 |
| US-20150322018-A1 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, F12, C5 | MEN1 778/4885KMT2A 2211/4885IL1B 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.